Lentiviral transduction reduces oncogene amplification in cancer cells, indicating a potential therapeutic approach.
Lentiviral transduction causes the depletion of cancer cells with extrachromosomally amplified oncogenes. A, Oncogene amplification status before and after lentiviral transduction. Parental PC3 cells and the transduced PC3 cells that underwent three cycles of lentiviral transduction followed by antibiotics selection were synchronized at metaphase and processed for FISH analysis. MYC probe (red) and chromosomal control probe (green) were used. The number of cells containing MYC amplification was quantified (n = 41). Bar = 10 μm. The lentiviral genome size for each cycle is indicated, along with the name of the antibiotics used in that cycle. Cells were transduced with lentivirus for 48 hours and subjected to antibiotics selection for 1–2 weeks. B, Graphical summary and statistical test of FISH analysis (χ² test, P < 0.0001). C, Oncogene amplification status before and after lentiviral transduction. The HeLa cell line that acquired methotrexate resistance (HeLa-MTX-Res) underwent two cycles of lentiviral transduction followed by antibiotics selection. Then, the cells were synchronized at metaphase and processed for FISH analysis. A DHFR probe (red) was used. The number of cells containing DHFR amplification was quantified (n = 33). Bar = 10 μm. The lentiviral genome size for each cycle is indicated, along with the names of the antibiotics used in that cycle. Cells were transduced with lentivirus for 48 hours and subjected to antibiotics selection for 1–2 weeks. D, Graphical summary and statistical test of FISH analysis (χ² test, P = 0.0006).
No takes yet. Share an insight, caveat, or question.
Yi et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: